How much is the pediatric drugs market worth, and how is it expected to expand?
The pediatric drugs market size has grown rapidly in recent years. It will grow from $157.0 billion in 2024 to $181.02 billion in 2025 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to demand for related medications, demand with high pediatric population, increased pediatric disease awareness, expansion of pediatric oncology, rise of digital health and telemedicine, and increased collaboration in pediatric drug development.
The pediatric drugs market size is expected to see rapid growth in the next few years. It will grow to $316.0 billion in 2029 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to increasing pediatric population, rising prevalence of pediatric mental health issues, rising number of children with chronic conditions, higher vaccination rate in children and rising demand for pediatric mental health medications. Major trends in the forecast period include personalized pediatric medicine, technological integration in pediatric drug delivery, telemedicine and digital health solutions, enhance pediatric clinical trials, and collaboration between pediatricians and pharmacists.
Get Your Free Sample of The Global Pediatric Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21249&type=smp
Which industry factors have accelerated the pediatric drugs market’s expansion?
The growing number of preterm births is expected to propel the growth of the pediatric drugs market going forward. Preterm births refer to babies born before 37 weeks of pregnancy, which is earlier than the typical 40-week gestation period. The growing number of preterm births is attributed to factors such as increased maternal age, lifestyle choices, medical conditions, multiple pregnancies, and inadequate prenatal care. Pediatric drugs are essential in aiding the health and development of preterm infants by offering targeted treatments for challenges such as respiratory problems, infections, and nutritional gaps. For instance, in December 2022, according to the report published by Tommy’s, a UK-based charity organization, in 2022, the percentage of premature live births in England and Wales was 7.9%, up from 7.5% in 2021. This represents over 53,000 babies born prematurely in 2022. Therefore, the growing number of preterm births are driving the growth of the pediatric drugs market.
What are the primary segments of the pediatric drugs market?
The pediatric drugs market covered in this report is segmented –
1) By Type: Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs
2) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Respiratory Disorder Drugs: Asthma Medications, Cystic Fibrosis Treatments, Bronchodilators, Corticosteroids
2) By Autoimmune Disorder Drugs: Immunosuppressants, Biologic Therapies, Disease-Modifying Antirheumatic Drugs (DMARDs)
3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs), Antiemetics, Antidiarrheals, Laxatives
4) By Cardiovascular Drugs: Antihypertensive Medications, Heart Failure Treatments, Antiarrhythmic Drugs, Lipid-lowering Agents
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/pediatric-drugs-global-market-report
Which firms are leading the pediatric drugs market?
Major companies operating in the pediatric drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Co., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Vertex Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Mallinckrodt, Torrent Pharmaceuticals Ltd, Sarepta Therapeutics, Zydus Cadila
Which market trends are set to define the future of the pediatric drugs market?
Major companies operating in the pediatric drugs market are focusing on developing innovative drugs, such as fully human monoclonal antibodies, to improve treatment outcomes and minimize side effects for young patients. A fully human monoclonal antibody (mAb) is an antibody that is entirely derived from human genetic sequences, minimizing the risk of immune system reactions compared to chimeric or humanized monoclonal antibodies. These antibodies are produced using advanced biotechnology techniques, such as transgenic mice with human antibody genes or phage display technology. For instance, in August 2022, Johnson and Johnson, a US-based pharmaceutical industry company, received FDA approval for STELARA (ustekinumab) treatment of pediatric patients aged six years and older with active psoriatic arthritis (PsA). This approval represents a significant advancement as STELARA is the first and only biologic therapy targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), key cytokines involved in inflammatory responses associated with autoimmune diseases. Active PsA is a rare condition that affects approximately 5-8% of children with chronic inflammatory arthritis, leading to symptoms such as joint swelling and skin lesions.
Which geographic trends are shaping the pediatric drugs market, and which region has the highest market share?
North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Pediatric Drugs Market Report 2025 Offer?
The pediatric drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Pediatric drugs are medications specifically formulated, dosed, or approved for use in infants, children, and adolescents. These drugs are designed to treat various medical conditions in pediatric patients, considering their unique physiological and metabolic differences from adults.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21249
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
